Video Experimental Relacionado

Updated: Sep 13, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Evaluación de la lipoproteína como un marcador pronóstico de la progresión de la enfermedad vascular aterosclerótica

Tiffany R Bellomo^1,2, Emily E Bramel¹, Jiwoo Lee¹

¹Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.R.B., E.E.B., J.L., S.U., A.F., Z.Y., S.K., B.T., S.H., P.N., A.P.P.).

|July 28, 2025

Resumen

Los niveles elevados de lipoproteína (Lp) predicen un mayor riesgo de desarrollar enfermedad arterial periférica y estenosis carotídea, y sus complicaciones posteriores. Esto pone de relieve Lp (a) como un biomarcador clave para la evaluación del riesgo de enfermedad vascular aterosclerótica.

Área de la Ciencia:

Medicina cardiovascular
Los biomarcadores
Biología vascular

Sus antecedentes:

Los tratamientos actuales para la enfermedad vascular aterosclerótica dejan un riesgo residual.
La lipoproteína (Lp) se investiga como un biomarcador predictivo.
La identificación de pacientes de alto riesgo para eventos extracoronarios es crucial.

Objetivo del estudio:

Evaluar la utilidad de Lp (a) en la identificación de pacientes con alto riesgo de enfermedad vascular aterosclerótica extracoronaria incidente.
Determinar el papel de Lp (a) en la predicción de las complicaciones de la enfermedad arterial periférica y la estenosis de la arteria carótida.

Principales métodos:

Análisis de 460,544 participantes en el Biobanco del Reino Unido con Lp (a) medido prospectivamente.
Regresiones de riesgos proporcionales de Cox utilizadas para modelar las asociaciones.
Lp (a) concentraciones relacionadas con la enfermedad arterial periférica incidente (EAP), estenosis carotídea y sucesivos eventos adversos importantes en las extremidades y accidente cerebrovascular.

Principales resultados:

Concentraciones medianas más altas de Lp observadas en pacientes con EAP incidente, eventos adversos importantes en las extremidades, estenosis carotídea incidente y progresión del ictus.
Un aumento de 75 nmol/ L en Lp (a) se asoció con un mayor riesgo de EAP incidente (HR 1.18) y estenosis carotídea (HR 1.17).
Los niveles altos de Lp (a) aumentaron significativamente el riesgo de eventos adversos importantes en las extremidades en pacientes con EAP (1, 57 veces) y mostraron una tendencia al accidente cerebrovascular en pacientes con estenosis carotídea (1, 40 veces).

Conclusiones:

Las concentraciones elevadas de Lp (a) están significativamente asociadas con la incidencia de la enfermedad vascular aterosclerótica extracoronaria.
Un Lp{a} elevado está relacionado con la progresión de estas enfermedades vasculares y sus principales complicaciones.

Palabras clave:

Progreso de la enfermedad aterosclerótica enfermedad vascular aterosclerótica extracoronaria Proteínas lipídicas

Más Videos Relacionados

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Videos de Conceptos Relacionados

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Peripheral Artery Disease I: Introduction

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...